Dental floss and stain-resistant carpets might expose people to per- and polyfluoroalkyl substances thought to be endocrine disruptors. (Journal of Exposure Science & Environmental Epidemiology)
Following oral arguments this week, Merck asked the Supreme Court to throw out a class-action lawsuit related to adverse effects of the osteoporosis drug alendronate (Fosamax). (The Epoch Times)
Did Coca-Cola and other junk food companies shape Chinese anti-obesity policy for their own benefit? One expert thinks so. (The BMJ)
The North American Menopause Society (NAMS) and Massachusetts General Hospital Midlife Women’s Health Center announced they’re collaborating together on a new questionnaire — the Vulvovaginal Atrophy Questionnaire — aimed at understanding and evaluating the genitourinary symptoms of menopause better. (Menopause)
In related news, the benefits of menopausal hormone therapy may extend to a reduced risk for knee osteoarthritis. “This study suggests that estrogen taken at menopause may inhibit cartilage damage and reduce knee deterioration seen on x-rays,” said JoAnn Pinkerton, MD, NAMS executive director, in a statement. (Menopause)
Amgen said its osteoporosis drug romosozumab (Evenity) was granted approval in Japan this week.
Omega-3 supplements for obese children didn’t improve insulin resistance or body weight in a randomized trial. (Pediatric Obesity)
A British teen born female but identifying as male is crowdfunding for donations to freeze his eggs before he undergoes testosterone hormonal therapy. (The London Economic)